ICER Chief: FDA Should ‘Get Its Act Together,’ Be More Transparent

By Beth Wang / July 16, 2021 at 8:02 PM
Institute for Clinical and Economic Review officials and outside advisers unanimously agreed there’s not enough evidence to show Biogen’s FDA-approved Alzheimer’s drug is effective, and they argued the approval raises questions about FDA’s trustworthiness and review procedures. ICER President Steven Pearson said the agency needs to “get its act together” and be transparent and consistent in its decision-making. The Aduhelm approval now puts providers who have defended FDA’s COVID-19 policies in an awkward position, one of the outside advisers said...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.